New oral immunomodulatory agents in the treatment of Relapsing-Remitting Multiple Sclerosis
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Wieczorek, Deborah | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Benkő, Ilona | |
| dc.contributor.opponentdept | Kenézy, Aneszteziológiai tanszék | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2014-06-22T16:05:54Z | |
| dc.date.available | 2014-06-22T16:05:54Z | |
| dc.date.created | 2014 | |
| dc.date.issued | 2014-06-22T16:05:54Z | |
| dc.description.abstract | The thesis talks about the newest oral immunomodulatory agents in the treatment of Multiple Sclerosis since its introduction in the year 2010 with focus on 2 drugs: Fingolimod and Teriflunomide. Both drugs have shown to reduce the disabiliy progression and annual relapse rate. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 30 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/194721 | |
| dc.language.iso | en | hu_HU |
| dc.rights.access | no_restriction | hu_HU |
| dc.subject | Multiple Sclerosis | hu_HU |
| dc.subject | Treatment | hu_HU |
| dc.subject.dspace | Fingolimod | hu_HU |
| dc.subject.dspace | Teriflunomide | hu_HU |
| dc.title | New oral immunomodulatory agents in the treatment of Relapsing-Remitting Multiple Sclerosis | hu_HU |